Earnings Report | 2026-05-05 | Quality Score: 93/100
Earnings Highlights
EPS Actual
$0.21
EPS Estimate
$None
Revenue Actual
$None
Revenue Estimate
***
Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies with attractive risk-reward profiles. Our valuation framework helps you find stocks with the right balance of growth and value characteristics for your portfolio. We provide P/E analysis, PEG ratios, and relative valuation metrics for comprehensive valuation coverage. Find value in growth with our comprehensive valuation analysis and multiples tools for growth at a reasonable price strategies.
National Research Corporation (NRC) released its official Q1 2026 earnings results earlier this month, marking the first public financial update for the healthcare market research and patient experience analytics firm this year. The only finalized financial metric shared in the initial release was adjusted earnings per share (EPS) of $0.21 for the quarter, with no consolidated revenue figures made available as of the current date. The release falls in line with standard regulatory reporting time
Executive Summary
National Research Corporation (NRC) released its official Q1 2026 earnings results earlier this month, marking the first public financial update for the healthcare market research and patient experience analytics firm this year. The only finalized financial metric shared in the initial release was adjusted earnings per share (EPS) of $0.21 for the quarter, with no consolidated revenue figures made available as of the current date. The release falls in line with standard regulatory reporting time
Management Commentary
During the accompanying public earnings call, National (NRC) leadership focused heavily on operational milestones achieved during Q1 2026, rather than uncompleted financial metrics not yet cleared for public disclosure. Key discussion points included the successful rollout of the company’s updated real-time patient feedback platform, which has been in pilot testing with several large regional health system clients in recent weeks. Management noted that early pilot results show the platform can reduce patient response times for feedback surveys by a significant margin, while also delivering more granular, actionable insights to care teams. Leadership also highlighted ongoing investments in AI-powered analytics capabilities designed to help clients identify unmet patient needs and reduce systemic care disparities, noting that client interest in these tools has increased notably in recent months. No specific commentary on top-line revenue performance was shared during the call, consistent with the limited financial data included in the initial release.
NRC (National) shares climb 2.85 percent in daily trading after posting Q1 2026 earnings per share of 21 cents.Access to multiple perspectives can help refine investment strategies. Traders who consult different data sources often avoid relying on a single signal, reducing the risk of following false trends.Some traders incorporate global events into their analysis, including geopolitical developments, natural disasters, or policy changes. These factors can influence market sentiment and volatility, making it important to blend fundamental awareness with technical insights for better decision-making.NRC (National) shares climb 2.85 percent in daily trading after posting Q1 2026 earnings per share of 21 cents.Scenario-based stress testing is essential for identifying vulnerabilities. Experts evaluate potential losses under extreme conditions, ensuring that risk controls are robust and portfolios remain resilient under adverse scenarios.
Forward Guidance
National (NRC) did not share formal quantitative forward guidance alongside its Q1 2026 earnings release, which is consistent with its historical reporting practices for quarters where full consolidated financial statements have not yet been finalized. Leadership did offer high-level qualitative outlook, noting that the company expects to continue prioritizing investments in product development and enterprise client expansion in the acute and ambulatory care spaces over the coming months. The team noted that evolving regulatory requirements for patient satisfaction reporting could drive additional demand for the firm’s solutions in the near to medium term, though no specific projections for client growth or market penetration were shared. Analysts tracking the space note that potential expansion into adjacent sectors, including senior care and post-acute rehabilitation services, could open new revenue streams for the firm, though no concrete plans for such expansion were confirmed during the call.
NRC (National) shares climb 2.85 percent in daily trading after posting Q1 2026 earnings per share of 21 cents.Technical analysis can be enhanced by layering multiple indicators together. For example, combining moving averages with momentum oscillators often provides clearer signals than relying on a single tool. This approach can help confirm trends and reduce false signals in volatile markets.Some investors rely heavily on automated tools and alerts to capture market opportunities. While technology can help speed up responses, human judgment remains necessary. Reviewing signals critically and considering broader market conditions helps prevent overreactions to minor fluctuations.NRC (National) shares climb 2.85 percent in daily trading after posting Q1 2026 earnings per share of 21 cents.The role of analytics has grown alongside technological advancements in trading platforms. Many traders now rely on a mix of quantitative models and real-time indicators to make informed decisions. This hybrid approach balances numerical rigor with practical market intuition.
Market Reaction
Following the release of NRC’s Q1 2026 earnings results, trading activity for the stock was within normal volume ranges in the first two trading sessions post-announcement, per available market data. Analysts covering National have noted that the reported $0.21 EPS figure is roughly aligned with broad market expectations for the quarter, though the lack of consolidated revenue data has contributed to muted short-term price action as investors wait for additional clarity. Several analyst notes published in recent days highlight that the company’s ongoing investments in AI-powered analytics could position it well to capture growing share of the healthcare patient intelligence market, though most firms are holding off on updating their performance estimates until the full 10-Q filing is released in the upcoming weeks. No major consensus estimate revisions have been recorded as of the current date.
Disclaimer: This analysis is for informational purposes only and does not constitute investment advice.
NRC (National) shares climb 2.85 percent in daily trading after posting Q1 2026 earnings per share of 21 cents.Data visualization improves comprehension of complex relationships. Heatmaps, graphs, and charts help identify trends that might be hidden in raw numbers.Cross-asset analysis provides insight into how shifts in one market can influence another. For instance, changes in oil prices may affect energy stocks, while currency fluctuations can impact multinational companies. Recognizing these interdependencies enhances strategic planning.NRC (National) shares climb 2.85 percent in daily trading after posting Q1 2026 earnings per share of 21 cents.Observing how global markets interact can provide valuable insights into local trends. Movements in one region often influence sentiment and liquidity in others.